1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
Oral Mucositis - Epidemiology Forecast to 2030

Oral Mucositis - Epidemiology Forecast to 2030

  • February 2021
  • 96 pages
  • ID: 6028050
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Oral Mucositis (OM) - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted OM epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Oral Mucositis (OM) Understanding

Oral Mucositis Overview
Mucositis occurs when cancer treatments break down the rapidly divided epithelial cells lining the gastrointestinal tract (which goes from the mouth to the anus), leaving the mucosal tissue open to ulceration and infection. The mucosa is the thin outer layer that lines most organs including the mouth, throat, esophagus, stomach, and bowel that communicate with the air, such as the respiratory and alimentary tracts, and have cells and associated glands that secrete mucus. The part of this lining that covers the mouth, called the oral mucosa, is one of the most sensitive parts of the body and is particularly vulnerable to chemotherapy and radiation. The oral cavity is the most common location for mucositis. Oral mucositis refers to the oral erythematous and ulcerative lesions commonly observed in patients undergoing cancer therapy. They are painful and affect nutrition and contribute to local and systemic infections.
Oral Mucositis Diagnosis
Clinical signs of mucosal damage and cell death appear after the first 1–2 weeks of radiation therapy and as early as 3 days after chemotherapy. Initial mucosal damage results in patchy erythema, edema, atrophy, and whitening of the mucosal tissue with increased sensitivity—patients report a burning sensation in the mouth. Further loss of mucosal epithelium becomes most prominent in the fourth or fifth week of standard fractionation radiation resulting in fibrinous exudation, confluent inflammation, and ulceration. The mouth sores and swelling can lead to significant oral pain, pain with swallowing, weight loss, and dehydration. Mucosal damage predisposes the patient to oral-super infection leading to further pain and alterations in taste and appetite and decreased quality of life.
Diagnosis is based on the symptoms the patient is experiencing and the appearance of the tissues of the mouth following chemotherapy, bone marrow transplants, or radiotherapy. Red burn-like sores or ulcers throughout the mouth is enough to diagnose mucositis. Oral mucositis is typically diagnosed based on the appearance, location, and timing of oral lessions, as well as the medical history, which may show a medication or treatment form that is highly linked with Oral Mucositis.
Useful laboratory tests for confirming diagnosis and etiology, especially if local fungal, bacterial, or viral infections infection is suspected, are complete blood count, Viral Culture, biopsy, and fungal testing. A wide variety of scales have been used to record the extent and severity of oral mucositis in clinical practice and research. The most commonly used scales are World Health Organization (WHO) Oral Toxicity score, The National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Radiation Therapy Oncology Group (RTOG) Scale, and Oral assessment guide for children & young people.
Epidemiology Perspective
The OM epidemiology division provides the insights about historical and current OM patient pool and forecasted trends for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings
In the year 2020, the total incident cases of Oral Mucositis were 1,480,453 cases in the 7MM. These cases are expected to grow in the study period 2018–2030.
The disease epidemiology covered in the report provides historical as well as forecasted OM epidemiology segmented as [Total Incident Cases of OM, Grade-specific cases of OM, and Treated cases of OM] scenario of OM in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- OM Epidemiology
Estimates show that the highest incident cases of OM in the 7MM were in the United States, followed by Japan in 2020.
• The United States, in 2020, accounted for 596,671, OM incident cases, which are expected to grow during the study period, i.e., 2018–2030.
• In the year 2020, the total incident cases of OM in EU5 were 623,424, which are expected to grow during the study period, i.e., 2018–2030.
• In the year 2020, the total incident cases of OM in Japan were 260,358, which are expected to grow during the study period, i.e., 2018–2030.

Scope of the Report
• The OM report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• The OM Report and Model provide an overview of the risk factors and global trends of OM in the seven major markets (7MM: The United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan)
• The report provides insight about the historical and forecasted patient pool of OM in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of OM.
• The report provides the segmentation of the OM epidemiology by incident cases in the 7MM.
• The report provides the segmentation of the OM epidemiology by grade-specific cases in the 7MM.
• The report provides the segmentation of the OM epidemiology by treated cases of OM in the 7MM.

Report Highlights

• 10-Year Forecast of OM epidemiology
• 7MM Coverage
• Total Incident Cases of OM
• Grade-Specific Cases of OM
• Treated cases of OM
KOL-Views
We interview KOL’s and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to OM?
• What are the key findings pertaining to the OM epidemiology across the 7MM and which country will have the highest number of patients during the study period (2018–2030)?
• What would be the total number of patients of OM across the 7MM during the study period (2018–2030)?
• Among the EU5 countries, which country will have the highest number of patients during the study period (2018–2030)?
• At what CAGR the patient population is expected to grow in the 7MM during the study period (2018–2030)?
• What are the various recent and upcoming events which are expected to improve the diagnosis of OM?

Reasons to buy
The OM Epidemiology report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the global OM market
• Quantify patient populations in the global OM market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for OM therapeutics in each of the markets covered
• Understand the magnitude of OM population by its severity
• The OM epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The OM Epidemiology Model developed is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2018–2030
• As per The estimates, in the United States, the total Grade-specific incident cases of Oral Mucositis were 156,729, 136,107, 209,660, and 94,175 for Grade I, Grade II, Grade III, and Grade IV, respectively in the year 2020. These cases are expected to grow in the study period 2018–2030.
• In Germany, the total treated cases of Oral Mucositis were 116,300 in the year 2020. These cases are expected to grow in the study period 2018–2030.
• In the 7MM, the total treated cases of Oral Mucositis were 1,066,151 in the year 2020.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Hunter Syndrome - Epidemiology Forecast–2030

  • $ 5200
  • February 2021
  • 100 pages

‘Hunter Syndrome - Epidemiology Forecast–2030’ report delivers an in-depth understanding of the disease, historical and forecasted Hunter Syndrome epidemiology in the United States, EU5 (Germany, ...

  • Spain
  • Germany
  • Epidemiology
  • Industry analysis
  • Life Expectancy

ref:plp2021

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on